Knockdown of NUAK2 promotes ferroptosis by regulating the mTOR/c-Myc signaling pathway to inhibit endometrial cancer cell progression

Background: Endometrial cancer (EC) represents a major gynecologic malignancy with unknown confirmed causes. Although NUAK family kinase 2 (NUAK2) is overexpressed and has been shown to promote progression in multiple cancers, its role in regulating ferroptosis in EC remains poorly understood. Methods: NUAK2 expression was analyzed using the Gene Expression Profiling Interactive Analysis (GEPIA) database. Western blot detection of protein levels of NUAK2, key ferroptosis regulators (solute carrier family 7 member 11 (SLC7A11) and Glutathione Peroxidase 4 (GPX4)), and major components of the mechanistic target of rapamycin (mTOR)/MYC Proto-Oncogene (c-Myc) signaling pathway. Intracellular ferrous ion (Fe2+) and Reactive Oxygen Species (ROS) levels were quantified to evaluate ferroptosis, small interfering RNA (siRNA)-mediated silencing of NUAK2 and pharmacological interventions, including Ferrostatin-1 (Fer-1) and the mTOR activator MHY1485, were performed to determine the underlying mechanisms. Results: NUAK2 was overexpressed in EC tissues and cell lines. Knockdown of NUAK2 significantly inhibited EC cell proliferation and induced ferroptosis, as indicated by elevated Fe2+ and ROS levels, together with decreased expression of the ferroptosis-related proteins SLC7A11 and GPX4. Mechanistically, NUAK2 knockdown inhibited activation of the mTOR/c-Myc signaling cascade, whereas treatment with the mTOR activator MHY1485 effectively counteracted the ferroptosis induction and proliferation inhibition resulting from NUAK2 silencing. Conclusions: Our findings demonstrate that NUAK2 knockdown promotes ferroptosis and suppresses the malignant progression of EC cells by inhibiting the mTOR/c-Myc signaling pathway. These findings support NUAK2 as a promising therapeutic target in EC treatment.

NUAK2; Endometrial cancer; Ferroptosis; mTOR/c-Myc pathway; Cell proliferation

[1] Corr BR, Erickson BK, Barber EL, Fisher CM, Slomovitz B. Advances in the management of endometrial cancer. The BMJ. 2025; 388: e080978.

[2] Eakin CM, Lai T, Cohen JG. Alarming trends and disparities in high-risk endometrial cancer. Current Opinion in Obstetrics and Gynecology. 2023; 35: 15–20.

[3] Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduction and Targeted Therapy. 2024; 9: 55.

[4] Dixon SJ, Pratt DA. Ferroptosis: a flexible constellation of related biochemical mechanisms. Molecular Cell. 2023; 83: 1030–1042.

[5] He H, Zhang J, Zhao Y. Ketamine inhibits endometrial cancer cell growth and motility by inducing ferroptosis. European Journal of Gynaecological Oncology. 2024; 45: 110–117.

[6] van de Vis RAJ, Moustakas A, van der Heide LP. NUAK1 and NUAK2 fine-tune TGF-beta signaling. Cancers. 2021; 13: 3377.

[7] Li Y, Song X, Liu L, Yue L. NUAK2 silencing inhibits the proliferation, migration and epithelial‑to‑mesenchymal transition of cervical cancer cells via upregulating CYFIP2. Molecular Medicine Reports. 2021; 24: 817.

[8] Worral Wilfred Raj AS, Manoharan R. NUAKs promote mTOR/c-Myc-induced glucose and glutamine reprogramming for cell growth and metastasis in breast cancer cells. Biochimica et Biophysica Acta—Molecular Basis of Disease. 2025; 1871: 167508.

[9] Fan J, Xue L, Lin H, Luo J. Depletion of NUAK2 blocks the stemness and angiogenesis and facilitates senescence of lung adenocarcinoma cells via enhancing ferroptosis. Cell Division. 2024; 19: 23.

[10] Wang Z, Ouyang L, Liu N, Li T, Yan B, Mao C, et al. The DUBA-SLC7A11-c-Myc axis is critical for stemness and ferroptosis. Oncogene. 2023; 42: 2688–2700.

[11] Hsin IL, Shen HP, Chang HY, Ko JL, Wang PH. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 positive feedback loop induces cell cycle arrest by dual PI3K/mTOR inhibitor PQR309 in endometrial cancer cell lines. Cells. 2021; 10: 2916.

[12] Chen B, Wang B, Xu X, Chen X, Yi W, Xu S, et al. Upregulation of NUAK2: a novel prognostic marker in breast cancer. Histol Histopathol. 2023; 38: 811–822.

[13] Tang L, Tong SJ, Zhan Z, Wang Q, Tian Y, Chen F. Expression of NUAK2 in gastric cancer tissue and its effects on the proliferation of gastric cancer cells. Experimental and Therapeutic Medicine. 2017; 13: 676–680.

[14] Singh T, Beatty A, Peterson JR. The AMPK-related kinase NUAK2 suppresses glutathione peroxidase 4 expression and promotes ferroptotic cell death in breast cancer cells. Cell Death Discovery. 2022; 8: 253.

[15] Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nature Reviews Clinical Oncology. 2021; 18: 280–296.

[16] Gong K, Zheng Y, Liu Y, Zhang T, Song Y, Chen W, et al. Phosphocholine inhibits proliferation and reduces stemness of endometrial cancer cells by downregulating mTOR-c-Myc signaling. Cellular and Molecular Life Sciences. 2024; 82: 3.

[17] Thepthanee C, Ei ZZ, Benjakul S, Zou H, Petsri K, Innets B, et al. Shrimp lipids inhibit migration, epithelial-mesenchymal transition, and cancer stem cells via Akt/mTOR/c-Myc pathway suppression. Biomedicines. 2024; 12: 722.

[18] Chen XJ, Guo CH, Yang Y, Wang ZC, Liang YY, Cai YQ, et al. HPV16 integration regulates ferroptosis resistance via the c-Myc/miR-142-5p/HOXA5/SLC7A11 axis during cervical carcinogenesis. Cell & Bioscience. 2024; 14: 129.

[19] Dai Y, Shi W, Qiu Y, Xu T, Lin J, Su Y. Circ_0000033 up‐regulates NUAK2 by sequestering miR‐378a‐3p to promote breast tumorigenesis. Environmental Molecular Mutagenesis. 2023; 64: 359–370.